Copner Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Copner Biotech is an early-stage innovator in the biofabrication and 3D cell culture space, operating from Cambridge and Ebbw Vale in the UK. The company's core offering is its 'Renderable Biofabrication' platform, centered on a proprietary 3D model data format (GRAPE®) and associated bioprinters, which together aim to standardize and improve the creation of complex tissue models for research. It generates revenue through the sale of PETG scaffolds and bioprinters, provides custom modeling services, and offers licensing for its patented technology. With initial academic testimonials highlighting ease of use and research utility, Copner is positioned to address the growing demand for advanced in vitro models in drug discovery and basic research.

AntibodiesDiagnostics

Technology Platform

Renderable Biofabrication® platform powered by the proprietary GRAPE® (Graphical Rectangular Actual Positional Encoding) 3D model data format for biofabrication, integrated with 3D/4D extrusion bioprinters and specialized 3D cell culture scaffolds.

Opportunities

The growing demand for physiologically relevant 3D cell culture models in drug discovery and academic research presents a large and expanding market.

The company's multi-faceted approach—selling tools, providing services, and licensing its IP—creates multiple revenue streams and pathways for market penetration.

Establishing the GRAPE® format as a standard could create a durable competitive moat and licensing royalty base.

Risk Factors

The company is a very early-stage startup facing significant competition from established players in bioprinting and scaffolds.

Its success is heavily dependent on widespread adoption of its proprietary GRAPE® data format, which carries technology adoption risk.

Limited financial resources and the technical challenges of consistently producing high-quality, complex biological prints pose substantial execution risks.

Competitive Landscape

Copner Biotech competes in the 3D bioprinting and advanced cell culture scaffold market against larger, established companies like CELLINK (BICO), Allevi (3D Systems), and Thermo Fisher Scientific, as well as numerous specialized startups. Its differentiation hinges on its integrated platform approach, specifically the GRAPE® data format aimed at standardization, and its focus on user-friendly, benchtop bioprinters for research labs.

More companies in United Kingdom →